 | • レポートコード：B-MOR-05231 • 出版社/出版日：Mordor Intelligence / 2018年4月 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、組織学および細胞学の世界市場について調べ、組織学および細胞学の世界規模、市場動向、市場環境、検査の種類別分析、テストの種類別分析、エンドユーザー別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・組織学および細胞学の世界市場インサイト ・組織学および細胞学の世界市場環境 ・組織学および細胞学の世界市場動向 ・組織学および細胞学の世界市場規模 ・組織学および細胞学の世界市場規模：検査の種類別 ・組織学および細胞学の世界市場規模：テストの種類別 ・組織学および細胞学の世界市場規模：エンドユーザー別 ・組織学および細胞学の世界市場：地域別市場規模・分析 ・組織学および細胞学の北米市場規模・予測 ・組織学および細胞学のアメリカ市場規模・予測 ・組織学および細胞学のヨーロッパ市場規模・予測 ・組織学および細胞学のアジア市場規模・予測 ・組織学および細胞学の日本市場規模・予測 ・組織学および細胞学の中国市場規模・予測 ・組織学および細胞学のインド市場規模・予測 ・組織学および細胞学の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global histology and cytology market is expected to register a CAGR of nearly 13.0% during the forecast period of 2018 – 2023. Histology and cytology belong to the scientific medical specialty dealing with human tissues and cells diagnostics, and this market is driven by the rising prevalence of cancer and extensive research and development in the diagnostics domain. The well-established healthcare infrastructure with better coverage of diagnosis and treatment through a wide network of diagnostic clinics, will help North America to dominate the market in the forecast period.
Growing Prevalence of Cancer
The growing prevalence of cancer patients has a direct impact on increased demand for the histology and cytology market. According to the 2012 report of the World Health Organization (WHO), there were 14 million new cases of cancers, which were expected to rise by about 70% over the next two decades. In the US, as per the National Cancer Institute report of 2018, an estimated 1.73 million new cases of cancer diagnosed in the United States and nearly 0.61 million people died from the disease. The histological methods help in increasing the sensitivity, specificity, and accuracy of diagnostic methods. Similarly, the combined methods help in better diagnosis of diseases such breast cancer and lung cancer. Thus, the prevalence of cancer plays a vital role in increasing the demand of histology and cytology market.
Other driving factors include increasing standardization of pathological laboratories, technological advancement in the diagnostics and molecular techniques, and favorable reimbursement for cancer screening and laboratory tests.
Saftey Issues and Diagnostic Accuracy Issues with Histopathological and Cytopathological Tests
The safety issues and diagnostic accuracy is one of the primary factor hindering this market. The safety issues are mainly related to potentially hazardous chemicals, biohazardous materials, accidents linked to the equipment and instrumentation. According to the 2013 publication in the Journal of Oral and Maxillofacial Pathology, even though the accuracy of frozen artifacts ranges between 89% — 98%, the frozen nature produces inferior slides for microscopic examination and sampling errors, which results from the heterogeneity of a tumor. Thus, this factor is one of the key aspects hindering the usage of histology and cytology in the research labs and diagnostic centers.
Another factor hindering the growth of this market is the lack of awareness among public for diagnostic tests.
Asia-Pacific to Register the Fastest Growth
Asia-Pacific is expected to dominate with the fastest growth rate in the forecast period. The healthy CAGR is expected due to the surge in the scientific researches in the South Asian countries. Novel opportunities are further enhanced by the rising number of long-term collaborations of multinational companies with domestic manufacturers and research laboratories in this region.
This is followed by the wide diversified patient pool of cancer and genetic disorders with rising role of personalized medicine in the treatment of genetic and other disorders. North America is expected to dominate the market with a large number of clinical research laboratories and academic institutes with better regulatory framework in the countries of this region.
Key Developments in the Market
• February 2018 – BD received premarket approval from the US FDA for the BD Onclarity HPV assay, which can detect 14 types of high-risk human papillomavirus (HPV) from the specimens collected for cervical cancer screening.
Major players: ABBOTT, BECTON DICKINSON AND COMPANY, DANAHER, F. HOFFMANN-LA ROCHE LTD, HOLOGIC, INC., MERCK KGAA, PERKINELMER, INC., SYSMEX CORPORATION, THERMO FISHER SCIENTIFIC, INC. AND TRIVITRON HEALTHCARE, amongst others.
Reasons to Purchase the Report
• Current and future of the global histology and cytology market outlook in the developed and emerging markets.
• Analysis of various perspectives of the market with the help of Porter’s Five Forces Analysis.
• The segment that is expected to dominate the market.
• Regions that are expected to witness the fastest growth during the forecast period.
• Identify the latest developments, market shares, and strategies employed by the major market players.
• 3-month analyst support, along with the Market Estimate sheet (in Excel).
Customization of the Report
This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry
6. Market Dynamics
6.1 Drivers
6.1.1 Rising Prevalence of Cancer
6.1.2 Increasing Standardization of Pathological Laboratories
6.1.3 Technological Advancement in the Diagnostic and Molecular Techniques
6.1.4 Favorable Reimbursements for Cancer Screening and Laboratory Tests
6.2 Restraints
6.2.1 Safety Issues and Diagnostic Accuracy Issues with Histopathological and Cytopathological Tests
6.2.2 Lack of Awareness among Public for Diagnostic Tests
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Type of Examination
7.1.1 Histology
7.1.2 Cytology
7.1.2.1 Breast Cancer
7.1.2.2 Cervical Cancer
7.1.2.3 Others
7.2 By Test Type
7.2.1 Microscopy-based Tests
7.2.1.1 Cytochemistry and Histochemistry
7.2.1.2 Immunohistochemistry and Immunofluoroscence
7.2.1.3 Others
7.2.2 Molecular Genetics Tests
7.2.2.1 Cytogenic Tests
7.2.2.1.1 Karyotyping
7.2.2.1.2 Fluorescent in Situ Hybridization (FISH)
7.2.2.2 Polymerase Chain Reaction
7.2.2.3 Others
7.2.3 Flow Cytometry
7.3 By End User
7.3.1 Hospitals/Clinics
7.3.2 Biopharmaceutical Companies
7.3.3 Academia
7.3.4 Others
7.4 By Geography
7.4.1 North America
7.4.1.1 United States
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.1.4 Rest of North America
7.4.2 Europe
7.4.2.1 France
7.4.2.2 Germany
7.4.2.3 United Kingdom
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest of Europe
7.4.3 Asia-Pacific
7.4.3.1 China
7.4.3.2 Japan
7.4.3.3 India
7.4.3.4 Australia
7.4.3.5 South Korea
7.4.3.6 Rest of Asia-Pacific
7.4.4 Middle East & Africa
7.4.4.1 GCC
7.4.4.2 South Africa
7.4.4.3 Rest of Middle East & Africa
7.4.5 South America
7.4.5.1 Brazil
7.4.5.2 Argentina
7.4.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Abbott
9.2 Becton Dickinson and Company
9.3 Danaher
9.4 F. Hoffmann-La Roche Ltd
9.5 Hologic, Inc.
9.6 Merck KGaA
9.7 PerkinElmer, Inc.
9.8 Sysmex Corporation
9.9 Thermo Fisher Scientific, Inc.
9.10 Trivitron Healthcare
*List not Exhaustive
10. Future of the Market
11. Disclaimer